CD8A and melanoma: The role of TRM CD8 T cells in improving anti-tumour efficacy has been demonstrated by a recombinant vaccinia virus (rVACV) carrying OVA in the V16-OVA melanoma growth model, as it was found that the generation of skin TRM cells is sufficient for effective antitumor immunity [184].